Determination of test performance of two contemporary screening tests for Lynch syndrome in endometrial cancer: A clinical trial
CONCLUSIONS: This study is the first, to our knowledge, to test the effectiveness of the bFHQ in an EC population since its original reporting; our results are consistent with many reports of the challenges of collecting family health history. The performance of the IHC test as a screen falls within ranges reported in the literature but do not provide the confidence to drive a decision for or against continued use of this test as a LS screen.PMID:34689999 | DOI:10.1016/j.ygyno.2021.09.022 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 25, 2021 Category: Cancer & Oncology Authors: James M Gudgeon Jeremy C Wallentine Emily M Bonham Hannah D McLaughlin Mark K Dodson Source Type: research

Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends
CONCLUSIONS: While most countries with cancer registry have shown reduction in cervical cancer incidence and mortality, the increasing incidence among younger women from some developed countries warrants further implementation of effective cancer screening.PMID:34688503 | DOI:10.1016/j.ygyno.2021.10.075 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 24, 2021 Category: Cancer & Oncology Authors: Wen-Qiang He Chenxi Li Source Type: research

A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
CONCLUSIONS: Oncolytic viral therapy with intraperitoneal Olvi-Vec showed promising safety, clinical activities, and immune activation in patients with PRROC, warranting further clinical investigation.PMID:34686353 | DOI:10.1016/j.ygyno.2021.10.069 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 23, 2021 Category: Cancer & Oncology Authors: Madhavi Manyam Amanda J Stephens Jessica A Kennard Jane LeBlanc Sarfraz Ahmad James E Kendrick Robert W Holloway Source Type: research

Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation
Gynecol Oncol. 2021 Oct 19:S0090-8258(21)01421-9. doi: 10.1016/j.ygyno.2021.10.003. Online ahead of print.NO ABSTRACTPMID:34686354 | DOI:10.1016/j.ygyno.2021.10.003 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 23, 2021 Category: Cancer & Oncology Authors: N S Horowitz R N Eskander M R Adelman W Burke Source Type: research

Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement
Gynecol Oncol. 2021 Oct 19:S0090-8258(21)01452-9. doi: 10.1016/j.ygyno.2021.10.008. Online ahead of print.NO ABSTRACTPMID:34686355 | DOI:10.1016/j.ygyno.2021.10.008 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 23, 2021 Category: Cancer & Oncology Authors: R Harrison I Zighelboim N G Cloven J Z Marcus R L Coleman A Karam Source Type: research

Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors
CONCLUSIONS: Genetic and clinical characteristics were predictive of higher CIPN symptomatology in gynecologic cancer survivors, and combining these factors resulted in superior predictive power compared with a model with clinical factors only. Prospective validation and assessment of clinical utility are warranted.PMID:34674889 | DOI:10.1016/j.ygyno.2021.10.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 22, 2021 Category: Cancer & Oncology Authors: Lauren Thomaier Burcu F Darst Patricia Jewett Cody Hoffmann Katherine Brown Aditi Makaram Anne Blaes Peter Argenta Deanna Teoh Rachel I Vogel Source Type: research

Trends in ureteral surgery on an academic gynecologic oncology service
CONCLUSIONS: Ureteral surgery is necessary in the case of injury or involvement with invasive disease. There has been a decrease in number of procedures. Ureteroneocystostomy has remained the most common method of reconstruction for both injury and resection with acceptable postoperative complication rates.PMID:34674890 | DOI:10.1016/j.ygyno.2021.10.009 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 22, 2021 Category: Cancer & Oncology Authors: Alexandra Martin Ali Wells Matthew L Anderson Jing-Yi Chern Thomas J Rutherford Mian M Shahzad Robert M Wenham Mitchel S Hoffman Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Corrigendum to "Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis" [Gynecologic Oncology 162 (2021) 532-538]
Gynecol Oncol. 2021 Oct 12:S0090-8258(21)01386-X. doi: 10.1016/j.ygyno.2021.09.017. Online ahead of print.NO ABSTRACTPMID:34654574 | DOI:10.1016/j.ygyno.2021.09.017 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 16, 2021 Category: Cancer & Oncology Authors: Kimberly Levinson Anna L Beavis Christopher Purdy Anne F Rositch Akila Viswanathan Aaron H Wolfson Michael G Kelly Krishnansu S Tewari Leah McNally Saketh R Guntupalli Omar Ragab Yi-Chun Lee David S Miller Warner K Huh Kelly J Wilkinson Nicola M Spirtos L Source Type: research

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
Gynecol Oncol. 2021 Oct 11:S0090-8258(21)01419-0. doi: 10.1016/j.ygyno.2021.10.001. Online ahead of print.ABSTRACTOBJECTIVE: We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).METHODS: 166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a bl...
Source: Gynecologic Oncology - October 15, 2021 Category: Cancer & Oncology Authors: F Gernier A Gompel C Rousset-Jablonski E Kalbacher A Floquet D Berton-Rigaud O Tredan J Alexandre P Follana A Zannetti N Dohollou J-M Grellard B Clarisse I Licaj D Ahmed-Lecheheb R Fauvet P Pautier F Joly Source Type: research

Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study
Gynecol Oncol. 2021 Oct 11:S0090-8258(21)01419-0. doi: 10.1016/j.ygyno.2021.10.001. Online ahead of print.ABSTRACTOBJECTIVE: We have previously shown that epithelial ovarian cancer (EOC) and its treatments have negative effects on long-term quality of life (QoL) and fatigue. The present multicenter study investigated the main menopausal symptoms and gynecological management of EOC survivors (EOCS).METHODS: 166 patients with relapse-free ≥3 years after the end of treatment attended a consultation with a gynecologist, including a questionnaire related to vasomotor symptoms (VMS) and sexuality, a clinical examination, a bl...
Source: Gynecologic Oncology - October 15, 2021 Category: Cancer & Oncology Authors: F Gernier A Gompel C Rousset-Jablonski E Kalbacher A Floquet D Berton-Rigaud O Tredan J Alexandre P Follana A Zannetti N Dohollou J-M Grellard B Clarisse I Licaj D Ahmed-Lecheheb R Fauvet P Pautier F Joly Source Type: research

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
CONCLUSION: Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients.PMID:34642026 | DOI:10.1016/j.ygyno.2021.09.025 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 13, 2021 Category: Cancer & Oncology Authors: G E Konecny A E Wahner Hendrickson T M Davidson B J Winterhoff S Ma S Mahner J Sehouli P A Fasching G Feisel-Schwickardi M Poelcher L D Roman A Rody B Y Karlan S A Mullany H Chen I L Ray-Coquard D M Provencher A Yachnin P H Cottu J A Glaspy P Haluska D J Source Type: research

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer
CONCLUSION: Addition of ganitumab to CP chemotherapy in primary EOC did not improve PFS. Our results do not support further study of ganitumab in unselected EOC patients.PMID:34642026 | DOI:10.1016/j.ygyno.2021.09.025 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 13, 2021 Category: Cancer & Oncology Authors: G E Konecny A E Wahner Hendrickson T M Davidson B J Winterhoff S Ma S Mahner J Sehouli P A Fasching G Feisel-Schwickardi M Poelcher L D Roman A Rody B Y Karlan S A Mullany H Chen I L Ray-Coquard D M Provencher A Yachnin P H Cottu J A Glaspy P Haluska D J Source Type: research

The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers
Gynecol Oncol. 2021 Oct;163(1):3-4. doi: 10.1016/j.ygyno.2021.09.001.NO ABSTRACTPMID:34629166 | DOI:10.1016/j.ygyno.2021.09.001 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 11, 2021 Category: Cancer & Oncology Authors: Kiran H Clair Robert E Bristow Source Type: research

The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers
Gynecol Oncol. 2021 Oct;163(1):3-4. doi: 10.1016/j.ygyno.2021.09.001.NO ABSTRACTPMID:34629166 | DOI:10.1016/j.ygyno.2021.09.001 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 11, 2021 Category: Cancer & Oncology Authors: Kiran H Clair Robert E Bristow Source Type: research

The urban-rural gap: Disparities in ovarian cancer survival among patients treated in tertiary centers
Gynecol Oncol. 2021 Oct;163(1):3-4. doi: 10.1016/j.ygyno.2021.09.001.NO ABSTRACTPMID:34629166 | DOI:10.1016/j.ygyno.2021.09.001 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 11, 2021 Category: Cancer & Oncology Authors: Kiran H Clair Robert E Bristow Source Type: research

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
CONCLUSIONS: In this Phase I study, DMUC4064A demonstrated a tolerable safety profile along with encouraging efficacy in the indication of platinum-resistant OC.PMID:34627611 | DOI:10.1016/j.ygyno.2021.09.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 10, 2021 Category: Cancer & Oncology Authors: Joyce Liu Howard Burris Judy S Wang Lisa Barroilhet Martin Gutierrez Yulei Wang Anjali Vaze Renee Commerford Stephanie Royer-Joo Voleak Choeurng Eric Humke Kathleen Moore Source Type: research

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)
CONCLUSION: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.PMID:34625284 | DOI:10.1016/j.ygyno.2021.09.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2021 Category: Cancer & Oncology Authors: R J Edmondson R L O'Connell S Banerjee L Mileshkin P Sykes P Beale A Fisher A Bonaventura D Millan S Nottley C Benson A Hamilton K Sjoquist L Alexander C Kelly K Carty L Divers N Bradshaw M Friedlander PARAGON investigators Source Type: research

Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903)
CONCLUSION: Whilst objective response rates with anastrozole are low, the clinical benefit rate and good tolerance suggests that aromatase inhibitor therapy may have a role in a subset of patients with metastatic LMS and UCS.PMID:34625284 | DOI:10.1016/j.ygyno.2021.09.010 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 9, 2021 Category: Cancer & Oncology Authors: R J Edmondson R L O'Connell S Banerjee L Mileshkin P Sykes P Beale A Fisher A Bonaventura D Millan S Nottley C Benson A Hamilton K Sjoquist L Alexander C Kelly K Carty L Divers N Bradshaw M Friedlander PARAGON investigators Source Type: research

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
CONCLUSIONS: Olaparib plus ceralasertib is well-tolerated. No objective responses occurred, though a signal of activity was seen particularly in disease associated with BRCA1. Further evaluation of this combination should include alternate dosing strategies in genomically-selected populations.PMID:34620496 | DOI:10.1016/j.ygyno.2021.08.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 8, 2021 Category: Cancer & Oncology Authors: Payal D Shah Stephanie L Wethington Cheyenne Pagan Nawar Latif Janos Tanyi Lainie P Martin Mark Morgan Robert A Burger Ashley Haggerty Haley Zarrin Diego Rodriguez Susan Domchek Ronny Drapkin Ie-Ming Shih Simon A Smith Emma Dean St éphanie Gaillard Debor Source Type: research

Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer
CONCLUSIONS: Olaparib plus ceralasertib is well-tolerated. No objective responses occurred, though a signal of activity was seen particularly in disease associated with BRCA1. Further evaluation of this combination should include alternate dosing strategies in genomically-selected populations.PMID:34620496 | DOI:10.1016/j.ygyno.2021.08.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 8, 2021 Category: Cancer & Oncology Authors: Payal D Shah Stephanie L Wethington Cheyenne Pagan Nawar Latif Janos Tanyi Lainie P Martin Mark Morgan Robert A Burger Ashley Haggerty Haley Zarrin Diego Rodriguez Susan Domchek Ronny Drapkin Ie-Ming Shih Simon A Smith Emma Dean St éphanie Gaillard Debor Source Type: research

Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338]
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01392-5. doi: 10.1016/j.ygyno.2021.09.019. Online ahead of print.NO ABSTRACTPMID:34607710 | DOI:10.1016/j.ygyno.2021.09.019 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: N M S Baldewpersad Tewarie W J van Driel M van Ham M W Wouters R Kruitwagen participants of the Dutch Gynecological Oncology Collaborator Group Source Type: research

MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma
CONCLUSIONS: MiRNA profiling did not identify biological differences between AA and Caucasian patients with USC. Upregulation of miR-223 may be a prognostic factor in USC.PMID:34607711 | DOI:10.1016/j.ygyno.2021.09.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Larissa Lee Brooke Howitt Teresa Cheng Martin King Konrad Stawiski Wojciech Fendler Dipanjan Chowdhury Ursula Matulonis Panagiotis A Konstantinopoulos Source Type: research

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01377-9. doi: 10.1016/j.ygyno.2021.09.008. Online ahead of print.ABSTRACTOBJECTIVE: To develop and validate a comprehensive overall survival (OS) risk-scoring model in women with endometrioid endometrial cancer (EC).METHODS: Patients with EC diagnosed from 2004 to 2013 were identified through the National Cancer Database (NCDB). Patients with known lymphovascular space invasion (LVSI) status who were treated surgically (with or without adjuvant therapy) were included. Cox proportional hazards analysis was used to identify prognostic factors for OS. This model was used to assign point...
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Mariam M AlHilli Lisa Rybicki Caitlin Carr Meng Yao Sudha Amarnath Roberto Vargas Robert Debernardo Chad Michener Peter G Rose Source Type: research

Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338]
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01392-5. doi: 10.1016/j.ygyno.2021.09.019. Online ahead of print.NO ABSTRACTPMID:34607710 | DOI:10.1016/j.ygyno.2021.09.019 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: N M S Baldewpersad Tewarie W J van Driel M van Ham M W Wouters R Kruitwagen participants of the Dutch Gynecological Oncology Collaborator Group Source Type: research

MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma
CONCLUSIONS: MiRNA profiling did not identify biological differences between AA and Caucasian patients with USC. Upregulation of miR-223 may be a prognostic factor in USC.PMID:34607711 | DOI:10.1016/j.ygyno.2021.09.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Larissa Lee Brooke Howitt Teresa Cheng Martin King Konrad Stawiski Wojciech Fendler Dipanjan Chowdhury Ursula Matulonis Panagiotis A Konstantinopoulos Source Type: research

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01377-9. doi: 10.1016/j.ygyno.2021.09.008. Online ahead of print.ABSTRACTOBJECTIVE: To develop and validate a comprehensive overall survival (OS) risk-scoring model in women with endometrioid endometrial cancer (EC).METHODS: Patients with EC diagnosed from 2004 to 2013 were identified through the National Cancer Database (NCDB). Patients with known lymphovascular space invasion (LVSI) status who were treated surgically (with or without adjuvant therapy) were included. Cox proportional hazards analysis was used to identify prognostic factors for OS. This model was used to assign point...
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Mariam M AlHilli Lisa Rybicki Caitlin Carr Meng Yao Sudha Amarnath Roberto Vargas Robert Debernardo Chad Michener Peter G Rose Source Type: research

Corrigendum to: Postoperative outcomes of primary and interval cytoreductive surgery for advanced ovarian cancer registered in the Dutch Gynecological Oncology Audit (DGOA) [Gynecologic Oncology Volume 162, Issue 2, August 2021, Pages 331-338]
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01392-5. doi: 10.1016/j.ygyno.2021.09.019. Online ahead of print.NO ABSTRACTPMID:34607710 | DOI:10.1016/j.ygyno.2021.09.019 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: N M S Baldewpersad Tewarie W J van Driel M van Ham M W Wouters R Kruitwagen participants of the Dutch Gynecological Oncology Collaborator Group Source Type: research

MicroRNA profiling in a case-control study of African American women with uterine serous carcinoma
CONCLUSIONS: MiRNA profiling did not identify biological differences between AA and Caucasian patients with USC. Upregulation of miR-223 may be a prognostic factor in USC.PMID:34607711 | DOI:10.1016/j.ygyno.2021.09.015 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Larissa Lee Brooke Howitt Teresa Cheng Martin King Konrad Stawiski Wojciech Fendler Dipanjan Chowdhury Ursula Matulonis Panagiotis A Konstantinopoulos Source Type: research

Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma
Gynecol Oncol. 2021 Oct 1:S0090-8258(21)01377-9. doi: 10.1016/j.ygyno.2021.09.008. Online ahead of print.ABSTRACTOBJECTIVE: To develop and validate a comprehensive overall survival (OS) risk-scoring model in women with endometrioid endometrial cancer (EC).METHODS: Patients with EC diagnosed from 2004 to 2013 were identified through the National Cancer Database (NCDB). Patients with known lymphovascular space invasion (LVSI) status who were treated surgically (with or without adjuvant therapy) were included. Cox proportional hazards analysis was used to identify prognostic factors for OS. This model was used to assign point...
Source: Gynecologic Oncology - October 5, 2021 Category: Cancer & Oncology Authors: Mariam M AlHilli Lisa Rybicki Caitlin Carr Meng Yao Sudha Amarnath Roberto Vargas Robert Debernardo Chad Michener Peter G Rose Source Type: research

Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01393-7. doi: 10.1016/j.ygyno.2021.09.020. Online ahead of print.NO ABSTRACTPMID:34602285 | DOI:10.1016/j.ygyno.2021.09.020 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Rebecca Landy Christopher Mathews Michael Robertson Charles L Wiggins Yolanda J McDonald Daniel W Goldberg Isabel C Scarinci Jack Cuzick Peter D Sasieni Cosette M Wheeler New Mexico HPV Pap Registry (NMHPVPR) Steering Committee Members Source Type: research

Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01383-4. doi: 10.1016/j.ygyno.2021.09.014. Online ahead of print.ABSTRACTPURPOSE: To investigate the incidence and survival outcomes of primary ovarian sarcoma compared to those of epithelial ovarian cancer.METHODS: Data on primary ovarian sarcoma patients (n = 1361) and epithelial ovarian cancer patients (n = 30,366) between 1999 and 2017 were obtained from the Korea Central Cancer Registry, and their respective age-standardized incidence rate (ASR) and relative survival rate were calculated and compared.RESULTS: Based on the ASR, the incidence of epithelial ovarian cancer was 4.75...
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Hyeong In Ha Sang-Hyun Cho Jiwon Lim Yeon Jee Lee Chong Woo Yoo Young-Joo Won Myong Cheol Lim Source Type: research

Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
CONCLUSION: Following VBT, patients with dMMR have poorer RFS compared to pMMR patients regardless of HIR/LIR risk classification. The prognosis of intermediate-risk EEC patients may lie more on a continuum dependent on molecular features rather than distinct clinicopathologic risk categories.PMID:34602287 | DOI:10.1016/j.ygyno.2021.09.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Jessie Y Li Henry S Park Gloria S Huang Melissa R Young Elena Ratner Alessandro Santin Shari Damast Source Type: research

Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement
CONCLUSION: The nomograms and cut-off levels can be used to assist in counseling for patients diagnosed with CHM.PMID:34602288 | DOI:10.1016/j.ygyno.2021.09.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Yvonne M Hoeijmakers Yalck K Eysbouts Leon F A G Massuger Rana Dandis Joanna Inthout N E van Trommel Petronella B Ottevanger Chris M G Thomas Fred C G J Sweep Source Type: research

Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers
CONCLUSIONS: A comprehensive histological examination considering architectural patterns and their heterogeneity can help in prognostication of HGSOCs.PMID:34602289 | DOI:10.1016/j.ygyno.2021.09.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Eros Azzalini Renzo Barbazza Giorgio Stanta Giorgio Giorda Lucia Bortot Michele Bartoletti Fabio Puglisi Vincenzo Canzonieri Serena Bonin Source Type: research

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01329-9. doi: 10.1016/j.ygyno.2021.08.030. Online ahead of print.ABSTRACTOBJECTIVE: To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.METHODS: This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), in...
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Elizabeth M Swisher Rebecca S Kristeleit Amit M Oza Anna V Tinker Isabelle Ray-Coquard Ana Oaknin Robert L Coleman Howard A Burris Carol Aghajanian David M O'Malley Alexandra Leary Stephen Welch Diane Provencher Geoffrey I Shapiro Lee-May Chen Ronnie Shap Source Type: research

Corrigendum to 'A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States' [Gynecologic Oncology 159 (2020) 344-353]
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01393-7. doi: 10.1016/j.ygyno.2021.09.020. Online ahead of print.NO ABSTRACTPMID:34602285 | DOI:10.1016/j.ygyno.2021.09.020 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Rebecca Landy Christopher Mathews Michael Robertson Charles L Wiggins Yolanda J McDonald Daniel W Goldberg Isabel C Scarinci Jack Cuzick Peter D Sasieni Cosette M Wheeler New Mexico HPV Pap Registry (NMHPVPR) Steering Committee Members Source Type: research

Incidence and treatment outcomes of ovarian sarcoma compared to epithelial ovarian cancer from the national cancer registry
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01383-4. doi: 10.1016/j.ygyno.2021.09.014. Online ahead of print.ABSTRACTPURPOSE: To investigate the incidence and survival outcomes of primary ovarian sarcoma compared to those of epithelial ovarian cancer.METHODS: Data on primary ovarian sarcoma patients (n = 1361) and epithelial ovarian cancer patients (n = 30,366) between 1999 and 2017 were obtained from the Korea Central Cancer Registry, and their respective age-standardized incidence rate (ASR) and relative survival rate were calculated and compared.RESULTS: Based on the ASR, the incidence of epithelial ovarian cancer was 4.75...
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Hyeong In Ha Sang-Hyun Cho Jiwon Lim Yeon Jee Lee Chong Woo Yoo Young-Joo Won Myong Cheol Lim Source Type: research

Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
CONCLUSION: Following VBT, patients with dMMR have poorer RFS compared to pMMR patients regardless of HIR/LIR risk classification. The prognosis of intermediate-risk EEC patients may lie more on a continuum dependent on molecular features rather than distinct clinicopathologic risk categories.PMID:34602287 | DOI:10.1016/j.ygyno.2021.09.018 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Jessie Y Li Henry S Park Gloria S Huang Melissa R Young Elena Ratner Alessandro Santin Shari Damast Source Type: research

Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement
CONCLUSION: The nomograms and cut-off levels can be used to assist in counseling for patients diagnosed with CHM.PMID:34602288 | DOI:10.1016/j.ygyno.2021.09.016 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Yvonne M Hoeijmakers Yalck K Eysbouts Leon F A G Massuger Rana Dandis Joanna Inthout N E van Trommel Petronella B Ottevanger Chris M G Thomas Fred C G J Sweep Source Type: research

Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers
CONCLUSIONS: A comprehensive histological examination considering architectural patterns and their heterogeneity can help in prognostication of HGSOCs.PMID:34602289 | DOI:10.1016/j.ygyno.2021.09.012 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Eros Azzalini Renzo Barbazza Giorgio Stanta Giorgio Giorda Lucia Bortot Michele Bartoletti Fabio Puglisi Vincenzo Canzonieri Serena Bonin Source Type: research

Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Gynecol Oncol. 2021 Sep 30:S0090-8258(21)01329-9. doi: 10.1016/j.ygyno.2021.08.030. Online ahead of print.ABSTRACTOBJECTIVE: To describe molecular and clinical characteristics of patients with high-grade recurrent ovarian carcinoma (HGOC) who had long-term responses to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib.METHODS: This post hoc analysis pooled patients from Study 10 (NCT01482715; Parts 2A and 2B; n = 54) and ARIEL2 (NCT01891344; Parts 1 and 2; n = 491). Patients with investigator-assessed complete or partial response per RECIST were classified based on duration of response (DOR): long (≥1 year), in...
Source: Gynecologic Oncology - October 4, 2021 Category: Cancer & Oncology Authors: Elizabeth M Swisher Rebecca S Kristeleit Amit M Oza Anna V Tinker Isabelle Ray-Coquard Ana Oaknin Robert L Coleman Howard A Burris Carol Aghajanian David M O'Malley Alexandra Leary Stephen Welch Diane Provencher Geoffrey I Shapiro Lee-May Chen Ronnie Shap Source Type: research

Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study
Gynecol Oncol. 2021 Sep 28:S0090-8258(21)01381-0. doi: 10.1016/j.ygyno.2021.09.013. Online ahead of print.ABSTRACTOBJECTIVE: Adult-type ovarian granulosa cell tumors (AGCTs) are hormonally active neoplasms with limited epidemiological data available. We evaluated the effect of parity and postmenopausal hormone therapy (HT) use on the risk of AGCT in a population-based case-control setting.METHODS: We identified all women diagnosed with AGCT during 1994-2015 (n = 505) from the Finnish Cancer Registry. For each case, five controls matched for age were selected from the National Population Registry, which also provided data o...
Source: Gynecologic Oncology - October 2, 2021 Category: Cancer & Oncology Authors: Saara Bryk Sushmita Katuwal Ulla-Maija Haltia Johanna Tapper Juha S Tapanainen Eero Pukkala Source Type: research

Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study
Gynecol Oncol. 2021 Sep 28:S0090-8258(21)01381-0. doi: 10.1016/j.ygyno.2021.09.013. Online ahead of print.ABSTRACTOBJECTIVE: Adult-type ovarian granulosa cell tumors (AGCTs) are hormonally active neoplasms with limited epidemiological data available. We evaluated the effect of parity and postmenopausal hormone therapy (HT) use on the risk of AGCT in a population-based case-control setting.METHODS: We identified all women diagnosed with AGCT during 1994-2015 (n = 505) from the Finnish Cancer Registry. For each case, five controls matched for age were selected from the National Population Registry, which also provided data o...
Source: Gynecologic Oncology - October 2, 2021 Category: Cancer & Oncology Authors: Saara Bryk Sushmita Katuwal Ulla-Maija Haltia Johanna Tapper Juha S Tapanainen Eero Pukkala Source Type: research

Fertility-sparing surgery and fertility preservation in cervical cancer: The desire for parenthood, reproductive and obstetric outcomes
Gynecol Oncol. 2021 Sep 25:S0090-8258(21)01334-2. doi: 10.1016/j.ygyno.2021.09.003. Online ahead of print.ABSTRACTOBJECTIVE: To evaluate the desire for parenthood and reproductive outcomes of young cervical cancer survivors who underwent fertility-sparing surgery or fertility preservation procedures for invasive cervical cancer.METHODS: All women
Source: Gynecologic Oncology - September 29, 2021 Category: Cancer & Oncology Authors: R C J van der Plas A M E Bos I M J ürgenliemk-Schulz C G Gerestein R P Zweemer Source Type: research